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Summary The authors attempted to investigate the host's immune response against colorectal carcinoma
through the expression of HLA-DR antigen on carcinoma cells (Ca) and on normal epithelia immediately
adjacent to carcinoma (AN) in relation to tumour progression. The expression of HLA-DR antigen on Ca and
on normal epithelia, both on AN and those 5 -10 cm removed from the carcinoma (RN), were examined
immunohistochemically. mRNAs of cytokines, IFN-y and TNF-a, were detected by reverse transcription-
polymerase chain reaction (RT-PCR) in both carcinoma and remote normal tissues. The expression of HLA-
DR antigen on AN was significantly increased compared with RN. Patients with tumours showing HLA-DR
staining both in Ca and AN were in less advanced Dukes' stages (Dukes' A or B) compared with those without
the stain. Furthermore, the expression of HLA-DR antigen in normal mucosa coincided significantly with the
existence of IFN-y mRNA. Detection in carcinoma tissues of IFN-y mRNA that leads to the induction of
HLA-DR antigen on AN could be an indicator of a host's immune response to carcinoma. These in vivo
observations might be clinically applicable to the prediction of patients' immune responsiveness to carcinomas.
Keywords: HLA-DR antigen; IFN-y mRNA; local immune response; tumour progression; immunohistochem-
istry; reverse transcription - polymerase chain reaction
It is still controversial whether or not HLA antigen
expression in carcinomas correlates with the development of
carcinoma and prognosis (McDougall et al., 1990; Moller et
al., 1991; Durrant et al., 1987), although a number of clinical
and experimental data have been published on this issue
(Krief et al., 1989; Andersen et al., 1993). The immune
responses involving HLA antigens expressed on carcinoma
cells are thought to play an important role in eliminating
mutated cells or suppressing carcinoma progression. As
reported in some recent studies, the reduced expression of
HLA antigens in colorectal tissues has been proposed as a
mechanism whereby carcinomas protect themselves from
hosts' immunosurveillance.
On the other hand, other experimental results have
indicated that normal epithelia in colorectal tissues do not
normally express HLA-DR antigen (Durrant et al., 1987;
Matsumoto et al., 1989; Horie et al., 1990; Garrido et al.,
1993; Selby et al., 1983). Therefore, the expression of HLA-
DR antigen on carcinoma cells or on normal epithelia might
be induced by interferon-y (IFN-y) produced by interstitial
cells, or tumour infiltrating lymphocytes (TIL) (Rognum et
al., 1987; Hamilton et al., 1991), as this cytokine reportedly
induces HLA-DR antigen in a variety of cell lines (Krief et
al., 1989; Lahat et al., 1993; Pober, 1988). It is also well
known that both tumour necrosis factor-a (TNF-ox) and IFN-
y can have either a synergistic or an antagonistic effect on the
immune system (Raitano and Korc, 1990; Watanabe and
Jacob, 1991).
In this study, the authors examined the expression of
HLA-DR antigen on carcinoma cells (Ca), normal epithelia
immediately adjacent to carcinoma (AN) and epithelia
obtained from remote normal tissues 5 10 cm away from
carcinoma (RN). At the same time, IFN-y and TNF-x
mRNAs in the tissues were analysed.
We also attempted to elucidate the significance of the
expressed HLA-DR antigen on carcinoma tissues by studying
the relation to the local immune responses of the host and
disease stages (Dukes' classification).
Patients, materials and methods
Patients
Forty-nine random Japanese patients with colorectal
adenocarcinomas (35 men and 14 women, age 35-84 years,
average 61.3 years) underwent resection at the Second
Department of Surgery of Chiba University Hospital
between May 1991 and August 1994. Routine histological
examination revealed that the majority of tumours (84%)
were well or moderately differentiated, and the remaining
(16%) poorly differentiated or mucinous adenocarcinomas.
Seventy per cent of the tumours originated in the sigmoid
colon or rectum. According to the Dukes' staging system,
22.4% were A, 28.6% B, 12.2% C and 36.7% D. These
percentages did not deviate much from larger series reported
in Japan.
Sets of tissue samples consisting of Ca, AN and RN were
obtained from all cases. Surgically resected specimens,
embedded in optimal cutting temperature compound
(OCT), were frozen in liquid nitrogen and stored at -80°C
until used.
Immunohistochemical procedures for HLA-DR antigen
Four micron cryostat sections mounted on slides and
pretreated with 5% Bioden meshcement/toluene were stained
immunohistochemically by the avidin-biotin complex
method (Hsu et al., 1981). Briefly, air-dried sections were
fixed in cold acetone for 20 min and washed with phosphate-
buffered saline (PBS) for 5 min. After pretreatment with
normal rabbit serum, the sections were incubated with
primary monoclonal antibodies at appropriate dilutions in a
humidified chamber for 1 h at room temperature. The
monoclonal antibody used in this study was HU-20, a
monomorphic anti-HLA-DR antibody (Koide et al., 1982).
After washing in PBS, the sections were incubated with
biotinylated anti-mouse immunoglobulin as a second anti-
body for 30 min. The sections were then incubated with
horseradish peroxidase-conjugated streptavidin-biotin com-
plex for 30 min. Peroxidase activity was visualised by DAB
solution (20 mg of 3,3'-diaminobenzidine, 65 mg of sodium
azide, and 10 ml of 30% hydrogen peroxide in 100 ml of
0.05 M Tris buffer at pH 7.6). Haematoxylin was used for
counterstaining.
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Microscopic evaluation was carried out as follows. Stained
sections were reviewed independently by at least two trained
pathologists (T T and K M). Cases with more than 10% of
carcinoma cells strongly stained in the membrane and/or
cytoplasm with HU-20 specific for HLA-DR antigen were
regarded as positive.
To test the specificity of the staining procedure, the
primary antibody, HU-20, was omitted in staining an HLA-
DR-positive tumour (as a negative control). To test the
specificity of the primary antibody, lymphocytes of the lymph
node were stained (as a positive control). For RN we took
into consideration the stain intensity as well as the stained
area, because in those epithelia positive staining was limited
to small areas near the lymph follicles.
RT-PCR
Total RNAs were extracted from colorectal tissues by the
guanidinium/caesium chloride procedure (Chirgwin et al.,
1979). To detect IFN-y and TNF-a mRNAs, reverse
transcription -polymerase chain reaction (RT-PCR) and
consecutive Southern blot analysis were performed. A
DNAase treatment was done before reverse transcription.
The sequences of the primers used in this study are 5'-
ATGAAATATACAAGTTATATCTTGGCTTT-3' (sense, nt
130- 158) and 5'-GATGCTCTTCGACCTCGAAACAGCA
T-3' (antisense, nt 598-623) for IFN-y, 5'-GTTCCTCAGC-
CTCTTCTCCT-3' (sense, nt 178-197) and 5'-GCAGGGG-
CTCTTGATGGCAG-3' (antisense, nt 597-616) for TNF-oc.
The respective PCR product sizes were 494 bp and 439 bp.
RT-PCR was performed with a commercially available
RT-PCR kit (Amersham). After converting 2 ig of each
total RNAs to cDNA, the samples were subjected to 34
amplification cycles (1 min at 94°C, 30 s at 54°C, 1.5 min at
72°C; complete cycle 8.5 min) in a PC-700 thermal cycler
(Astec). Beta-actin was used as an internal control to
confirm the amplification condition. The PCR reaction
mixtures contained 5 ,ul of 10 x Taq polymerase buffer,
200 ,UM dNTPs, 100 pmol of primers and 2.5 units of Taq
DNA polymerase in a final volume of 50 p,l.
Each 10 jul of PCR products was electrophoresed on 1.5%
agarose gel and subsequently transferred onto nylon
membrane filters. The membranes were hybridised with the
PCR product amplified by the same primers for IFN-y and
by an internal probe for TNF-ax. These probes had been
labelled with [32P]a-deoxynucleoside triphosphates with a
random primed DNA labelling kit (Amersham). To confirm
the accuracy of PCR, each PCR product was digested with
restriction enzymes, DraI for IFN-y and PvuII for TNF-ax.
Results
Immunohistochemical staining for HLA-DR antigen
As shown in Table I, the proportions of HLA-DR antigen-
positive cases were 27 of 49 (55.1%) on Ca and 37 of 49
(75.5%) on AN. In comparison, the expression of HLA-DR
Table I Frequency of positive HLA-DR stain (positive cases/
examined cases) in relation to tissue
Location
HLA antigen Ca AN RN
HU20 27/49 37/49 10/49
(class II-DR) (55.1%) (75.5%) (20.4%)
I ~~~~~~~*
The expression of HLA-DR antigens was significantly increased on
carcinoma (Ca; 55.1 %) and normal epithelia immediately adjacent to
the carcinoma (AN; 75.5%) compared with remote normal epithelia
5 10 cm away from carcinoma (RN; 20.4%). * P<0.01.
.V.
Figure 1 Examples of immunohistochemical staining of HLA-DR antigen expression on colorectal carcinoma cells (Ca) and
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Figure 2 Heterogeneous expression of HLA-DR antigen on a
colorectal carcinoma lesion.
antigen on RN was observed in only 10 of 49 cases (20.4%).
The expression of HLA-DR antigen on Ca and AN was
significantly greater (P<0.01) than that on RN.
As shown in Figure 1, the expression of HLA-DR antigen
did not coincide between Ca and AN in some cases (Figures
lb and c) and four different combinations were discerned. In
approximately one-third of the HLA-DR-positive carcinoma
tissues, both positive and negative portions were randomly
seen side by side (Figure 2).
Detection of IFN-y and TNF-oa mRNA in tissues
Enzyme digestion of IFN-y with DraI and TNF-a with PvuII
produced fragments of 240 bp and 277 bp respectively, thus
confirming that the PCR product sizes were correct.
Figure 3 shows representative RT-PCR and Southern
blotting analysis of IFN-y and TNF-a products. As shown in
cases 1, 3, 5, 6 and 7, IFN-y was detected in tumour tissues
(T) but not in remote normal tissues (N). In these five cases
HLA-DR antigen was expressed in AN but not in Ca or RN.
In case 4 IFN-y mRNA was detected in both T and N, and
HLA-DR antigen was also expressed in Ca, AN and RN.
Alternatively, in case 8 IFN-y was absent in both T and N,
and HLA-DR antigen was not expressed in Ca, AN or RN,
although liver metastasis tissue (M) showed a positive HLA-
DR antigen expression. Figure 3 also indicates that the
expression of HLA-DR antigen in normal epithelia, both AN
and RN is significantly concordant with the existence of IFN-
y mRNA. In addition, in some cases (1, 2, 3, 5, 6 and 7)
HLA-DR antigen expression was different between Ca and
AN even though both IFN-y and TNF-a were detected.
TNF-a was detected along with IFN-y in 21 of 42 (50.0%).
Table II shows the correlation between HLA-DR antigen
expression in the tissues and IFN-y. IFN-y mRNA was
detected more frequently in T compared with N. HLA-DR
antigen expression was apparent in 63.0% of Ca and in
88.9% of AN. In contrast, in RN without IFN-y mRNA,
HLA-DR antigen was not expressed in 91.7% of the cases. In
normal epithelia, the sum of AN and RN, the correlation
between HLA-DR antigen expression and the detection of
IFN-y mRNA in the tissues was even more significant (X2
test, P<0.01).
Case no. 1 2 3 4 5 6 7
T N T N T N T N T N T N T N M T N M
HLA-DRantigen - - - +











Figure 3 Detection of IFN-y and TNF-a mRNA by RT-PCR and consecutive Southern blot assay. T, carcinoma tissues including
carcinoma cells (Ca) and normal epithelia immediately adjacent to carcinoma (AN); N, remote normal tissues obtained 5-0cm
away from the carcinoma (RN); M, liver metastasis; C, control.
Table II Relationship between HLA-DR antigen expression and IFN-y mRNA
Ca AN RN
IFN-y mRNA IFN-y mRNA IFN-y mRNA IFN-y mRNA IFN-y mRNA IFN-y mRNA
HLA-DR + + +
+ 17 8 24 8 6 2
(63.0%) (88.9%)
10 7 3 7 10 22
(91.7%)
Total 27 15 27 15 16 24
HLA-DR antigen expression was apparent in 63.0% (Ca) and 88.9% (AN) ofcases where IFN-y mRNA was detected in tumour tissues. In the
portions ofremote normal tissues (N) where IFN-y mRNA was not detected, HLA-DR antigen expression on RN was not detected in 91.7% ofthe
cases. In normal epithelia, including both AN and RN, thecorrelation between HLA-DR antigen expression and the detection ofIFN-y mRNA was
even more significant (P<0.01). aNS (n =42). bp<0.05 (n =42). cP<0.05 (n =40).Colorectal carcinoma progression/HLA-DR antigen
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Table III Correlation between HLA-DR antigen expression in tissues and stage of disease (Dukes' classification)
Dukes' stages
HLA-DR No. IFN-y
Ca AN (n=49) A B C D detected (%)
(a) + + 23 -00000 0000 0 -000 15/21
0 000 00
(46.9%) A (8) (7) (3) iA (5) (71.4%)
(b) + - 4 0 0 2/4
00
(8.2%) (0) (2) (1) (1) (50.0%)
(c) + 14 @00 0 00000 9/11
0 0
(28.6%) A (2) AA (5) (2) (5) (81.8%)
(d) - - 8 0 1/6
0 0000
(16.3%) (1) (0) (0) AA (7) (16.7%)
Thecasesexaminedwere classified into fourgroupswith respect to the HLA-DRantigenexpression oncarcinomacells(Ca) and normalepithelia
immediately adjacent to carcinoma (AN). The clinical stages ofthese four groups and the relation to IFN-y mRNA detected in the tissues are also
analysed. Dukes' stages of the type (d) patients are significantly more advanced (P<0.05) than type (a) patients. 0,IFN-y mRNA detected;
0,IFN-y mRNA not detected; A, not done. *P<0.05.
Correlation between HLA-DR antigen expression in carcinoma
tissues and its clinicopathological stages
Table III gives all the cases as classified into four groups
based on HLA-DR antigen expression in Ca and AN, clinical
stages and detection of IFN-y mRNA in the tissue. The
distribution of these four groups were: 46.9% expressed
HLA-DR on both Ca and AN (type a), 8.2% only on Ca
(type b), 28.6% only on AN (type c), and 16.3% on neither
Ca nor AN (type d). Representative immunohistochemical
staining of each of these groups is shown in Figure 1.
In type (a) patients, Dukes' stages A and B were 15
(65.2%), C and D were 8 (34.8%). By contrast, in type (d)
patients, Dukes' A, B and C, D were 1 (12.5%) and 7
(87.5%), respectively. In other words, type (d) patients were
significantly advanced (P<0.05) compared with type (a)
patients. As regards IFN-y mRNA detected in the tissue, type
(a) patients (15 of 21, 71.4%) were more frequently positive
compared with type (d) patients (1 of 6, 16.7%).
Discussion
Recent studies have shown that the local immune response of
the host is closely related to the progress, growth and/or
invasion of carcinoma cells. It is well established that CD8+
T (cytotoxic) cells and CD4+ T (helper) cells are restricted by
HLA class I and class II molecules respectively (McDougall
et al., 1990; James et al., 1991). It has thus been proposed
that carcinoma cells that can evoke an immune response in
vivo due to the expression of tumour-associated antigens
(TAA) can escape recognition and subsequent lysis by loss of
the expression of HLA class I molecules (Moller et al., 1991;
Krief et al., 1989).
It has also been reported that tumour cells that express
HLA class II molecules (especially HLA-DR antigen) can act
as antigen-presenting cells (APC) inducing cytotoxic T
lymphocytes (CTL) that recognise TAA, namely CD4+ class
II restricted CTL (James et al., 1991). Recent experimental
data in vitro have demonstrated that IFN-y can induce HLA-
DR antigen on several kinds of cells (Balkwill, 1989;
Dinarello and Mier, 1987; Gumina et al., 1991; Tomoda et
al., 1992). In this paper we have tried to show that HLA-DR
antigen expression on epithelial cells in colorectal carcinoma
tissues correlates with tumour progression and IFN-y
production, possibly by tumour-infiltrating lymphocytes
(TILs) (Hamilton et al., 1991).
As shown in Tables I and II, HLA-DR antigen expression
on carcinoma tissues, Ca and AN, was significantly greater
than on RN. In addition, a significant correlation was
observed between HLA-DR antigen expression on normal
epithelia and the presence of IFN-y mRNA in tissues.
Immunohistochemically, all cases examined could be
classified into four groups according to HLA-DR antigen
expression on Ca and AN (Figure 1 and Table III). These
results could indicate that the regulatory mechanisms for
HLA-DR antigen expression on Ca are different from those
for AN in some cases (Lahat et al., 1993). The following
possibilities may be considered to explain this phenomenon.
Firstly, TNF-a may up-regulate or down-regulate IFN-y-
induced HLA-DR antigen expression depending on the stage
of differentiation and maturation of the carcinoma cell
(Watanabe and Jacob, 1991). In addition, IFN-y and TNF-
a have synergistic effects in suppressing carcinoma cell
growth (Raitano and Korc, 1990; Sugarman et al., 1985).
Secondly, the receptor for IFN-y or signal transduction
pathways on these carcinoma cells might be different from
those of normal epithelia (Gumina et al., 1991). Finally, there
also remains the possibility that carcinoma cells regulate their
own HLA-DR antigen and modulate or escape the local
immune responses.
The reason why IFN-y mRNA was scarcely detected in
type (d) patients (Table III) may be related to the number or
function of TIL in tissue. For example, the number of TIL
decreases in advanced breast, stomach and colon carcinomas
(Watt and House, 1978). Furthermore, the 4 chain of the T
cell receptor complex on TIL has been shown to decrease or
vanish in some advanced carcinomas (Mizoguchi et al., 1992;
Nakagomi et al., 1993).
Figure 2 shows the heterogeneous expression of HLA-DR
antigen on carcinoma cells, a phenomenon also reported by
other groups (Rognum et al., 1987). HLA-DR antigen
positive carcinoma cells are distributed more heteroge-
neously in well differentiated adenocarcinomas than in
poorly differentiated ones (data not shown). These results
indicate that well differentiated and relatively benign
adenocarcinomas are composed of multiple clones.
Our results raise several questions. (1) Is the expression of
HLA-DR antigen on carcinoma cells a result ofcytokines, or
do carcinoma cells regulate HLA-DR antigen expression by
themselves? (2) Is the focal expression of HLA-DR antigen
on carcinoma cells an indication of multiple clones (Lampert
et al., 1985)? (3) Which cells express IFN-y and TNF-oe and
where are they localised in relation to normal and/or tumour
cells? Answers to these questions will require considerable
further study.
In the present study we also used immunohistochemical
staining to examine HLA-class I antigen expression using the
monoclonal antibody w6/32, which recognises the common
epitope of HLA-A, -B and -C antigens. There was no
significant difference in the tissues observed (data not shown),
although allelic loss of one or more class I molecules is
reported in colorectal carcinomas (Versteeg et al., 1989). It
would be of particular interest to detect such loss andColorectal carcinoma progression/HLA-DR antigen
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correlate this to the presence or absence of HLA-DR antigen
and the degree ofmalignancy, in order to understand tumour
escape mechanisms better.
Taken together, it appears important to investigate HLA-
DR antigen expression not only on carcinoma cells but also
on adjacent normal epithelia in order to evaluate the local
immune response of the host. There is a possibility that
HLA-DR antigen expression on carcinoma tissues may
provide a clue to the understanding of the therapeutic
mechanisms of biological response modifiers or immunother-
apy which might act through the induction of HLA-DR
antigen on carcinoma cells.
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